This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Myrexis Presents Oral Anti-Interferon Data At American College Of Rheumatology/Association Of Rheumatology Health Professionals

SALT LAKE CITY, Nov. 8, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented key preclinical findings of the Company's novel oral anti-interferon (OAI), MPI-0485520, at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP), in Atlanta, Georgia.

A poster titled, "Inhibition of Cytosolic Nucleic Acid Receptor Pathways Using the Small Molecule IKKepsilon/TBK1 Kinase Inhibitor." showed that MPI-0485520 effectively suppressed the induction of several key pro-inflammatory proteins in vitro. The data supports the further evaluation of MPI-0485520 for the treatment of autoimmune disorders, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

"Our studies suggest MPI-0485520 may be an effective treatment for many autoimmune disorders, including rheumatoid arthritis and lupus" said Robert Carlson, Ph.D., Vice President and Head of Research at Myrexis. "MPI-0485520 inhibits production of type-1 interferon response and by blocking this response with our IKKepsilon inhibitor, there is the potential for disrupting disease processes."

Key Findings:

MPI-0485520 is a potent and selective inhibitor of key pro-inflammatory kinases

MPI-0485520 inhibits the activity of I kappa B kinase epsilon (IKK epsilon) and TANK-binding kinase 1 (TBK1), with picomolar potency. Conversely, MPI-0485520 did not significantly inhibit the activity of more than the 140 human kinases also tested in this study.

MPI-0485520 suppresses on-target pro-inflammatory cytokines, including IFNalpha/beta and downstream interferon-stimulated genes

The Company demonstrated that MPI-0485520 selectively inhibited production of many of the well known pro-inflammatory cytokines that are often induced in a diseased state. MPI-0485520 specifically suppressed the induction of type-1 interferon and several downstream interferon-stimulated genes including most notably, B lymphocyte stimulator (BLyS). BLys which is the target of belimumab which is currently under review by the FDA for treatment of systemic lupus erythematosus (SLE). Unlike potential competitors, MPI-0485520 is a small molecule, rather than a biologic and therefore may be developed as a daily oral therapy, and Furthermore, MPI-0485520 it targets a more central immune response regulator and thus has the potential to be effective against a variety of autoimmune diseases.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,083.80 -2.83 -0.02%
S&P 500 1,987.98 +0.97 0.05%
NASDAQ 4,472.1080 -1.5890 -0.04%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs